Opus Genetics (IRD) Stock Forecast & Price Target

Opus Genetics is attractive because it has multiple near-term clinical catalysts, led by OPGx-LCA5 and OPGx-BEST1, with FDA alignment on pivotal designs, dosing expected to begin this quarter or in 4Q26, and several data readouts concentrated in 2027. The company also has meaningful non-dilutive and partnered economics from phentolamine ophthalmic solution 0.75%, including a $10M milestone expected in 4Q26, up to $130M in total milestones, and royalties starting in the low teens, while its cash runway extends into 2029 without assuming PRV monetization. Fundamentally, the pipeline is backed by encouraging early efficacy signals, including a 75% responder rate in BEST1 Cohort 1 and sustained long-term LCA5 responses, plus upside from PRVs and additional programs such as RDH12, MERTK, and RHO.

Opus Genetics is a high-risk, development-stage company whose value depends heavily on two lead gene therapy assets, OPGx-LCA5 and OPGx-BEST1, while the broader pipeline remains early and unproven. Its clinical evidence is still limited to small, early-stage cohorts, including a five-patient low-dose OPGx-BEST1 dataset and an OPGx-LCA5 registrational study that has completed enrollment in its six-month run-in period but has not yet begun treatment dosing, making efficacy and durability uncertain. Financially, the company has incurred significant losses since inception, has one partnered revenue-generating product, and may need substantial additional capital despite a cash runway expected to extend into 2029, creating dilution risk alongside commercialization and regulatory uncertainty.